Literature DB >> 16291034

Phosphodiesterase-5 inhibition: the molecular biology of erectile function and dysfunction.

Sharron H Francis1, Jackie D Corbin.   

Abstract

This article discusses the role of phosphodiesterase-5 (PDE-5) inhibition in the molecular biology of erectile function and dysfunction. Commercially marketed PDE-5 inhibitors are highly specific for PDE-5, and in the face of continuing cyclic GMP (cGMP) synthesis,elevate cellular cGMP. This elevation results from direct competitive inhibition of PDE-5 and from blocking the negative feedback regulation of the enzyme. Elevation of cGMP activates cGMP-dependent protein kinase, which mediates the effects of the cGMP-signaling pathway to decrease smooth muscle tone and dilate penile vascular smooth muscle. By exploiting features of PDE-5 regulatory mechanisms that modulate PDE-5 function, the inhibitors enhance their own potencies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16291034     DOI: 10.1016/j.ucl.2005.08.001

Source DB:  PubMed          Journal:  Urol Clin North Am        ISSN: 0094-0143            Impact factor:   2.241


  7 in total

Review 1.  cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action.

Authors:  Sharron H Francis; Jennifer L Busch; Jackie D Corbin; David Sibley
Journal:  Pharmacol Rev       Date:  2010-09       Impact factor: 25.468

2.  The role of cGMP-dependent protein kinase in controlling cardiomyocyte cGMP.

Authors:  Sharron H Francis
Journal:  Circ Res       Date:  2010-11-12       Impact factor: 17.367

3.  Allosteric-site and catalytic-site ligand effects on PDE5 functions are associated with distinct changes in physical form of the enzyme.

Authors:  Jackie D Corbin; Roya Zoraghi; Sharron H Francis
Journal:  Cell Signal       Date:  2009-08-06       Impact factor: 4.315

4.  Sildenafil and vardenafil but not nitroglycerin limit myocardial infarction through opening of mitochondrial K(ATP) channels when administered at reperfusion following ischemia in rabbits.

Authors:  Fadi N Salloum; Yuko Takenoshita; Ramzi A Ockaili; Vladimir P Daoud; Eric Chou; Kazu-ichi Yoshida; Rakesh C Kukreja
Journal:  J Mol Cell Cardiol       Date:  2006-12-08       Impact factor: 5.000

Review 5.  Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond.

Authors:  George S Baillie; Gonzalo S Tejeda; Michy P Kelly
Journal:  Nat Rev Drug Discov       Date:  2019-08-06       Impact factor: 84.694

Review 6.  Phosphodiesterase type 5 inhibitors: back and forward from cardiac indications.

Authors:  C Corinaldesi; L Di Luigi; A Lenzi; C Crescioli
Journal:  J Endocrinol Invest       Date:  2015-06-28       Impact factor: 4.256

7.  In Vivo Targeted Metabolomic Profiling of Prostanit, a Novel Anti-PAD NO-Donating Alprostadil-Based Drug.

Authors:  Ksenia M Shestakova; Natalia E Moskaleva; Natalia V Mesonzhnik; Alexey V Kukharenko; Igor V Serkov; Igor I Lyubimov; Elena V Fomina-Ageeva; Vladimir V Bezuglov; Mikhail G Akimov; Svetlana A Appolonova
Journal:  Molecules       Date:  2020-12-13       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.